Alpha 2.0
Login Register
» Authors » Shilpa Sayana

Shilpa Sayana

Explore the profile of Shilpa Sayana including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 12
Citations 35
Followers 0
Related Specialties
Infectious Diseases
General Medicine
Top 10 Co-Authors
Homayoon Khanlou
Michael Weinstein
Jorge Saavedra
Rishi Manchanda
Marjan Javanbakht
Gerald Hamwi
Peter Reis
Catherine Chien
Lisha Wilson
Susan Sanchez
Published In
J Int Assoc Physicians AIDS Care (Chic)
Expert Rev Anti Infect Ther
J Acquir Immune Defic Syndr
Am J Med Sci
Lancet
Affiliations
Soon will be listed here.
Recent Articles
1.
Use of maraviroc-, raltegravir-, and etravirine-containing regimens in treatment-experienced patients: a case-series study
Youngblood C, Sayana S, Khanlou H
J Int Assoc Physicians AIDS Care (Chic) . 2011 Mar; 10(3):135-7. PMID: 21430236
The development of newer agents such as raltegravir, etravirine and maraviroc has improved the perspective of viral load suppression. However, there is not enough data regarding their use together. In...
2.
Clinical impact and cost of laboratory monitoring need review even in resource-rich setting
Sayana S, Javanbakht M, Weinstein M, Khanlou H
J Acquir Immune Defic Syndr . 2011 Feb; 56(3):e97-8. PMID: 21317583
No abstract available.
3.
The 104 day report: a successful intervention of improving patient retention
Sayana S, Javanbakht M, Weinstein M, Khanlou H
Clin Infect Dis . 2010 Sep; 51(7):868-9. PMID: 20809839
No abstract available.
4.
DART and laboratory monitoring of HIV treatment
Sayana S, Manchanda R, Khanlou H, Saavedra J, Reis P, Weinstein M
Lancet . 2010 Mar; 375(9719):979. PMID: 20304235
No abstract available.
5.
An unusual pathogen for a liver abscess in a human immunodeficiency virus-infected individual
Sayana S, Ricaurte J, Khanlou H
Am J Med Sci . 2010 Mar; 339(3):290-1. PMID: 20220339
Pyogenic liver abscesses are rarely encountered in HIV-infected patients living outside of temperate climates and are usually polymicrobial in nature, with a majority of the pathogens arising from gastrointestinal flora....
6.
Avoid a different standard of care when applying results of Development of Antiretroviral Therapy in Africa (DART) study
Sayana S, Manchanda R, Khanlou H, Saavedra J, Reis P, Weinstein M
J Acquir Immune Defic Syndr . 2009 Dec; 53(1):153-4. PMID: 20035167
No abstract available.
7.
Maraviroc: a new CCR5 antagonist
Sayana S, Khanlou H
Expert Rev Anti Infect Ther . 2009 Jul; 7(1):9-19. PMID: 19622053
Maraviroc is a small molecule and a member of a new class of antiretroviral compounds known as CCR5 antagonists, which block R5-tropic HIV entry into CD4 cells. HIV entry into...
8.
Analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and quality of life at 24 weeks
Sayana S, Prosser P, Ricaurte J, Sanchez S, Hamwi G, Hershey-Weber J, et al.
J Int Assoc Physicians AIDS Care (Chic) . 2009 Apr; 8(2):85-6. PMID: 19369697
No abstract available.
9.
The use of darunavir/ritonavir as intensification in low viremic HIV-infected patients treated with boosted protease inhibitor-containing regimens
Sayana S, Hamwi G, DenOuden P, Easley A, Khanlou H
J Int Assoc Physicians AIDS Care (Chic) . 2009 Jan; 8(1):21-2. PMID: 19171916
No abstract available.
10.
No residual activity of raltegravir after development of 148 complex mutations in vivo
Khanlou H, Sayana S, Acosta E
J Int Assoc Physicians AIDS Care (Chic) . 2009 Jan; 7(6):281-2. PMID: 19164138
No abstract available.